CSF Aβ42 predicts early-onset dementia in Parkinson disease.
about
Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's DiseaseHarnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and ChallengesWhat is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and DiagnosisThe role of biomarkers and imaging in Parkinson's disease.Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease.Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson diseaseLewy body dementias.Slowing of EEG background activity in Parkinson's and Alzheimer's disease with early cognitive dysfunctionCSF biomarkers and clinical progression of Parkinson disease.Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of Alzheimer's disease.CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.α-Synuclein increases β-amyloid secretion by promoting β-/γ-secretase processing of APP.CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson DiseaseEffects of Heart Bypass Surgery on Plasma Aβ40 and Aβ42 Levels in Infants and Young Children.Parkinson's Disease with Fatigue: Clinical Characteristics and Potential Mechanisms Relevant to α-Synuclein Oligomer.Reliability of Three Disability Scales for Detection of Independence Loss in Parkinson's Disease.CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.Impulsive and Compulsive Behaviors in Parkinson's Disease: The Norwegian ParkWest Study.Imaging the role of amyloid in PD dementia and dementia with Lewy bodies.Biomarkers in biological fluids for dementia with Lewy bodies.Cognitive function in the early phase of Parkinson's disease, a five-year follow-up.Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.Advances in Biomarker Research in Parkinson's Disease.Cognitive decline in Parkinson disease.Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review.Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.Association of a BACE1 Gene Polymorphism with Parkinson's Disease in a Norwegian Population.Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease1.Network connectivity determines cortical thinning in early Parkinson's disease progression.Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.Changes of cerebrospinal fluid Aβ42, t-tau, and p-tau in Parkinson's disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis.Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.α-Synuclein Heterocomplexes with β-Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity.
P2860
Q26744782-3971AF79-E916-468A-85C7-C0957F568DDEQ28072061-CCB1B21E-7FD3-4A9E-A1CE-0BA75654D621Q28083203-8FB7F467-8CEF-4567-904E-6474640A6D76Q28384572-B55AF48F-CA7A-408B-B4C9-DAB506A0EBD3Q31041660-88D22806-929E-4BDE-B045-68499263E15AQ33574058-DE9AFBC7-3CB3-4F9C-947F-1E9AB57C9840Q33698810-D4B9AD87-E06E-46DC-BD76-B33F75E88831Q34502646-D1448563-056F-4B4C-8DA2-78F42CE16CBEQ34531520-80F695CD-C6FB-40A4-8A4B-535FBB0CBC26Q35106542-D0E084B8-A9B9-4178-9C38-FF454FC229CEQ35858648-B3B56F53-A220-4DCD-8AB3-580A0A63A0F0Q36169215-99EE5F98-52C0-4CB4-AA4C-A36204F30BFDQ36277049-7585739E-1452-4156-ACE9-F2BD3881F6A6Q36535217-74609A7B-B64F-4B9E-BABD-45B79A80025BQ36580926-0ED8A12C-990D-4FD2-8A89-11E2049BD4DAQ36789528-FC2E6681-F147-41A1-8479-7171D0081D42Q36880831-97CF0A1C-A316-4BF6-ADAA-C94722490307Q37272860-1CEE557E-CF81-40F9-9C28-2A1ADDF7B219Q37273088-F8D5E8C8-8594-4521-B425-AA07686B7EFBQ37345484-35D5B0C2-88A6-4F40-A42C-85F38BF72C67Q37494873-CD2199B4-092F-4ACE-9394-64863648290BQ37635622-7521F015-2BFC-4388-B29A-EC3A2194D376Q38228098-5C5A70F0-235E-44D2-9B86-CE6D88D5EBACQ38283550-C4F6A503-77ED-4D9C-8617-F30AFC087458Q38416865-8C4072AC-2316-4F0B-BDCC-5BFE9D957FFDQ38603309-F0F3B107-184E-4B9D-8B30-B97C4E7454B6Q38669168-184C3E14-5534-4C27-9A0C-C0DF6B019BE7Q38681599-BC382115-AD54-4F75-A752-8F6FDC8333CDQ38751099-63246A04-634F-4674-B283-3F061E80E7ECQ38780220-EE8FA855-3A46-4548-9C83-D51025DA3951Q40604774-2799EF83-FFE1-46AC-84E5-5C6E351F7CF5Q40777128-03C650BA-F8E4-44E3-83BD-CF8FA789FB3CQ41163005-A924EC41-1444-488C-B39D-652650D63376Q42178133-72BB4F40-7EA5-4A08-B90E-4F8382A649C3Q46255370-06A3F547-5AF1-4716-8EEB-E86A8ACD76FBQ47566459-82384FB6-E838-40CA-92BE-E5F4B613272BQ47657093-23E3E470-95E1-4B62-A95F-3B5C3D679251Q48238518-8CE26332-AAA9-451C-A6B2-D2650E021119Q50666330-2C559F59-696A-4BFD-89D5-A468FAADEC65Q51764708-06A057E0-E7AA-47A2-990D-71606D7CED7A
P2860
CSF Aβ42 predicts early-onset dementia in Parkinson disease.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
CSF Aβ42 predicts early-onset dementia in Parkinson disease.
@en
CSF Aβ42 predicts early-onset dementia in Parkinson disease.
@nl
type
label
CSF Aβ42 predicts early-onset dementia in Parkinson disease.
@en
CSF Aβ42 predicts early-onset dementia in Parkinson disease.
@nl
prefLabel
CSF Aβ42 predicts early-onset dementia in Parkinson disease.
@en
CSF Aβ42 predicts early-onset dementia in Parkinson disease.
@nl
P2093
P50
P1433
P1476
CSF Aβ42 predicts early-onset dementia in Parkinson disease.
@en
P2093
Jan P Larsen
Johannes Lange
Kenn F Pedersen
Marthe G Førland
Ulf Andreasson
P304
P356
10.1212/WNL.0000000000000425
P407
P577
2014-04-18T00:00:00Z